EP: 6 OMIDRIA Special Ep. 6 Innovations in Dropless Cataract Surgery Solutions



Dr. Eric Donnenfeld
Dr. Eric Donnenfeld is an internationally recognized surgeon and expert in refractive, cornea and cataract surgery in the United States.  He has won numerous awards, including being named Newsweek’s best ophthalmologist in America in both 2022 and 2021. He is currently a National Medical Director of TLC Laser Eye Centers and Surgical Director of the Lions Eye Bank for Long Island.

Dr. John Hovanesian
Dr. John Hovanesian is a cataract, corneal, and laser eye surgeon.  He was recognized by Newsweek as one of the top 35 eye surgeons in the United States and by The Ophthalmologist as one of the world’s 100 most influential people in eye care.  He is the owner of Harvard Eye Associates in California.



In this episode of ‘Peer2Peer: The Podcast’, Dr. Eric Donnenfeld and Dr. John Hovanesian discuss a recent clinical study evaluating clinical efficacy and patient preference for a dropless treatment regimen following cataract surgery, as well as other innovative dropless solutions.


Key Takeaways:

  • Challenges with Conventional Drop Usage: Donnenfeld discusses the 5 C’s relating to drug delivery and topical drops, highlighting issues surrounding compliance, corneal toxicity, comfort, cost, and cosmesis.
  • The Importance of a Non-Steroidal: Donnenfeld and Dr. Hovanesian question whether steroid, non-steroidal, and antibiotic drugs are really all necessary and agree that the non-steroidal is the most important part of a post-operative regimen for cataract surgery.
  • Linchpin to Cataract Surgery: Donnenfeld believes that non-steroidals are the linchpin to cataract surgery, preventing inflammation and preventing CME, as well as providing comfort to the patient because they reduce inflammation and pain post-surgery.
  • A Powerful Combination: OMIDRIA is a combination drug that consists of Phenylephrine 1% and Ketorolac 0.3%. Dr. Donnenfeld and Dr. Hovanesian highlight its ability to maintain mydriasis, reduce complications, decrease surgical time, and improve patient comfort.
  • Study Findings on a Dropless Regimen: Donnenfeld and Dr. Hovanesian share results from their study comparing a traditional three-drop regimen versus a dropless regimen. There was no difference in clinical outcomes, but 95% of patients said when given the choice, they absolutely preferred the dropless regimen.
  • The Future of Drops: Dr. Donnenfeld and Dr. Hovanesian conclude by acknowledging that relying on three different drops for surgery is not necessary, and that using sustained drug delivery methods such as OMIDRIA can make surgery safer and improve patient outcomes.


OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.

OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.


Please see the Full Prescribing Information for OMIDRIA.



Additional Resources:

Follow Dr Eric Donnenfeld on social:
Dr Eric Donnenfeld | LinkedIn

Follow Dr John Hovanesian on social:
Dr John Hovanesian | LinkedIn

Peer2Peer educational platform:


Dr. Donnenfeld and Dr. Hovanesian’s study comparing a traditional three- drop regimen with a dropless treatment regimen including OMIDRIA



US-OM-2300050 01/24